SOMNIGROUP INTERNATIONAL INC. (SGI) Stock
SGI has an Alpha Score of 38 out of 100 (weak), computed on Oct 31, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 14 trades in SGI since 2025: 7 purchases and 7 sales, most recently April McClain Delaney (sale, Aug 25, 2026). 7 of the hedge funds AlphaScala tracks reported SGI in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $225.67M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Nov 3, 2026. Its trailing P/E ratio is 27.4 and its net margin 7.0% (key statistics as of Oct 22, 2026).
What is SGI's Alpha Score?
How it works →Alpha Score of 38 reflects weak overall profile with poor momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 31, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded SOMNIGROUP INTERNATIONAL INC. (SGI)?
Most recent: April McClain Delaney (sale, Aug 25, 2026); records start Jun 24, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| April McClain Delaney D-MD · House | 2026-08-25 | sale | $100k – $250k |
| April McClain Delaney D-MD · House | 2026-07-30 | purchase | $15k – $50k |
| April McClain Delaney D-MD · House | 2026-03-31 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-03-16 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-03-13 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-03-09 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-02-09 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-01-22 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026.
See all SGI political trades →Which hedge funds own SGI?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 2.88M | $225.67M | +30% |
| Third Point Dan Loeb | 2.57M | $201.55M | +13% |
| Citadel Ken Griffin | 1.70M | $133.45M | +146% |
| Marshall Wace | 322K | $25.28M | -45% |
| Soros Fund Management George Soros (founder) | 14K | $1.06M | -92% |
| Bridgewater Associates Ray Dalio | 6K | $473.2K | NEW |
| Millennium Management Israel Englander | 3K | $200.5K | -95% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are SOMNIGROUP INTERNATIONAL INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 27, 26 | Thompson Scott L | CEO & PRESIDENT | BUY | 30.0K | $1.9M |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →What are SGI's key statistics?
Key statistics as of Oct 22, 2026
How does SGI's valuation compare with the Consumer Discretionary sector?
| Metric | SGI | Consumer Discretionary median | Companies in median |
|---|---|---|---|
| P/E ratio | 27.4 | 21.0 | 126 |
| Net margin | 7.00% | 7.02% | 141 |
| Return on equity | 17.11% | 17.54% | 138 |
Medians over the Consumer Discretionary stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.
SGI price chart
Powered by TradingViewWhat does SOMNIGROUP INTERNATIONAL INC. do?
SomniGroup International Inc. is a key player in the global pharmaceutical and healthcare industry. Its primary function is to research, develop, and market innovative healthcare solutions aimed at improving health outcomes worldwide. SomniGroup is well-regarded for its development of life-saving medications and therapies focused on chronic and rare diseases, as well as its cutting-edge contributions to vaccine technology. The company has a diverse portfolio that includes over-the-counter pharmaceuticals, prescription drugs, and biotech products, serving a broad range of sectors from hospitals and clinics to retail pharmacies and healthcare providers. Headquartered strategically to leverage global supply chains, SomniGroup International Inc. plays a vital role in advancing medical science and enhancing public healthcare systems. By continually investing in R&D and forming strategic partnerships, the company remains at the forefront of delivering health innovations that meet both current and future needs of the medical industry.